Join
Live feed
·
INSIDERFilingvia Quantisnow
Janux Therapeutics Inc. logo

Chief Strategy Officer Robinson Byron was granted 28,000 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
JANX· Janux Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JANX (Janux Therapeutics Inc.) and more on Quantisnow.

Chief Strategy Officer Robinson Byron was granted 28,000 shares (SEC Form 4) | Quantisnow